DOCSLIB.ORG

LHCGR (Luteinizing Hormone/Choriogonadotropin Receptor); LPHN2 (Latrophilin 2) (1P31.1)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
LHCGR (Luteinizing Hormone/Choriogonadotropin Receptor); LPHN2 (Latrophilin 2) (1P31.1) Atlas of Genetics and Cytogenetics in Oncology and Haematology Home Genes Leukemias Solid Tumours Cancer-Prone Deep Insight Portal Teaching X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA Atlas Journal Atlas Journal versus Atlas Database: the accumulation of the issues of the Journal constitutes the body of the Database/Text-Book. TABLE OF CONTENTS Volume 8, Number 1, Jan-Mar 2004 Previous Issue / Next Issue Genes ATBF1 (AT-binding transcription factor 1) (16q22.3-q23.1). Nadine Van Roy, Frank Speleman. Atlas Genet Cytogenet Oncol Haematol 2004; 8 (1): 1-7. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/ATBF1ID357.html DIRC2 (3q21). Anita Bonné, Danièlle Bodmer, Marc Eleveld, Eric Schoenmakers, Ad Geurts van Kessel.. Atlas Genet Cytogenet Oncol Haematol 2004; 8 (1): 8-11. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/DIRC2ID497.html DIRC3 (2q35). Anita Bonné, Danièlle Bodmer, Marc Eleveld, Eric Schoenmakers, Ad Geurts van Kessel.. Atlas Genet Cytogenet Oncol Haematol 2004; 8 (1): 12-14. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/DIRC3ID498..html RAP1GDS1 (4q22.3). Franck Viguié. Atlas Genet Cytogenet Oncol Haematol 2004; 8 (1): 15-18. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/RAP1GDS1ID400.html RET (REarranged during Transfection) (10q11.2). Patricia Niccoli-Sire. Atlas Genet Cytogenet Oncol Haematol 2004; 8 (1): 19-25. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/RETID76.html LHCGR (luteinizing hormone/choriogonadotropin receptor); LPHN2 (latrophilin 2) (1p31.1). Jim Heighway. Atlas Genet Cytogenet Oncol Haematol 2004; 8 (1): 26-36. [Full Text] [PDF] Atlas Genet Cytogenet Oncol Haematol 2004; 1 I URL : http://AtlasGeneticsOncology.org/Genes/LHRID288.html LPHN2 (latrophilin 2) (1p31.1). Jim Heighway. Atlas Genet Cytogenet Oncol Haematol 2004; 8 (1): 37-42. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/LPHH1ID313.html HLXB9 (homeo box HB9) (7q36.3). Anne RM von Bergh, H Berna Beverloo. Atlas Genet Cytogenet Oncol Haematol 2004; 8 (1): 43-47. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/HLXB9ID393.html SYNPO2 (4q27). Jian-Hua Luo. Atlas Genet Cytogenet Oncol Haematol 2004; 8 (1): 48-51. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/SYNPO2ID488.html Leukaemias 11p15 rearrangements in treatment related leukemia. Jean-Loup Huret. Atlas Genet Cytogenet Oncol Haematol 2004; 8 (1): 52-53. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/11p15TreatRelLeukID1299.html 12p13 rearrangements in treatment related leukemia. Jean-Loup Huret. Atlas Genet Cytogenet Oncol Haematol 2004; 8 (1): 54-55. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/12p13TreatRelLeukID1301.html 21q22 rearrangements in treatment related leukemia. Jean-Loup Huret. Atlas Genet Cytogenet Oncol Haematol 2004; 8 (1): 56-57. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/21q22TreatRelLeukID1296.html inv(16)(p13q22) in treatment related leukemia. Jean-Loup Huret. Atlas Genet Cytogenet Oncol Haematol 2004; 8 (1): 58-59. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/inv16p13q22TreatRelID1297.html t(3;21)(q26;q22) in treatment related leukemia. Jean-Loup Huret. Atlas Genet Cytogenet Oncol Haematol 2004; 8 (1): 60-61. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/t0321q26q22TreatRelID1294.html t(8;16)(p11;p13) in treatment related leukemia. Jean-Loup Huret. Atlas Genet Cytogenet Oncol Haematol 2004; 8 (1): 62-63. [Full Text] [PDF] Atlas Genet Cytogenet Oncol Haematol 2004; 1 II URL : http://AtlasGeneticsOncology.org/Anomalies/t0816p11p13TreatRelID1302.html t(8;21)(q22;q22) in treatment related leukemia. Jean-Loup Huret. Atlas Genet Cytogenet Oncol Haematol 2004; 8 (1): 64-65. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/t0821q22q22TreatRelID1293.html t(9;22)(q34;q11) in treatment related leukemia. Jean-Loup Huret. Atlas Genet Cytogenet Oncol Haematol 2004; 8 (1): 66-67. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/t0922q34q11TreatRelID1300.html t(15;17)(q22;q21) in treatment related leukemia. Jean-Loup Huret. Atlas Genet Cytogenet Oncol Haematol 2004; 8 (1): 68-69. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/t1517q22q21TreatRelID1298.html Acute megakaryoblastic leukemia (AMegL); M7 acute non lymphocytic leukemia (M7- ANLL). Antonio Cuneo, Francesco Cavazzini, Gianluigi Castoldi. Atlas Genet Cytogenet Oncol Haematol 2004; 8 (1): 70-74. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/M7ANLLID1100.html Refractory anemia with excess blasts (RAEB). Antonio Cuneo, Francesco Cavazzini, Gianluigi Castoldi. Atlas Genet Cytogenet Oncol Haematol 2004; 8 (1): 75-78. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/RAEBID1105.html Refractory anemia (RA). Antonio Cuneo, Francesco Cavazzini, Gianluigi Castoldi. Atlas Genet Cytogenet Oncol Haematol 2004; 8 (1): 79-82. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/RAID1104.html Refractory anemia with ringed sideroblasts (RARS). Antonio Cuneo, Francesco Cavazzini, Gianluigi Castoldi. Atlas Genet Cytogenet Oncol Haematol 2004; 8 (1): 83-86. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/RARSID1106.html Solid Tumours Bladder: Urothelial carcinomas - updated. Angela van Tilborg, Bas van Rhijn. Atlas Genet Cytogenet Oncol Haematol 2004; 8 (1): 87-104. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Tumors/blad5001.html Soft tissue tumors: Elastofibroma. Roberta Vanni. Atlas Genet Cytogenet Oncol Haematol 2004; 1 III Atlas Genet Cytogenet Oncol Haematol 2004; 8 (1): 105-109. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Tumors/ElastofibromaID5173.html Ovary: Sex cord-stromal tumors. Lisa Lee-Jones. Atlas Genet Cytogenet Oncol Haematol 2004; 8 (1): 110-124. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Tumors/OvarSexCordStromID5223.html Testis: Spermatocytic seminoma. Ewa Rajpert-De Meyts. Atlas Genet Cytogenet Oncol Haematol 2004; 8 (1): 125-131. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Tumors/SpermatSeminID5119.html Cancer Prone Diseases Familial clear cell renal cancer. Anita Bonné, Danielle Bodmer, Marc Eleveld, Eric Schoenmakers, Ad Geurts van Kessel.. Atlas Genet Cytogenet Oncol Haematol 2004; 8 (1): 132-135. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Kprones/FamClearCellRenalID10081.html Deep Insights Case Reports Educational Items © Atlas of Genetics and Cytogenetics in Oncology and Haematology X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA Home Genes Leukemias Solid Tumours Cancer-Prone Deep Insight Portal Teaching For comments and suggestions or contributions, please contact us [email protected]. Atlas Genet Cytogenet Oncol Haematol 2004; 1 IV Atlas of Genetics and Cytogenetics in Oncology and Haematology ATBF1 (AT-binding transcription factor 1) Identity Other AT motif-binding factor 1 names Alpha-fetoprotein enhancer binding protein Hugo ATBF1 Location 16q22.3-q23.1 DNA/RNA Description 10 exons, DNA size: 261.32 kb. Transcription two isoforms ATBF1-A and ATBF1-B, due to alternative promotor usage combined with alternative splicing, mRNA-size: 11893 bp. Protein Description 3703 amino acids; 404 kDa; four homeodomains and 23 zinc fingers including 1 pseudo zinc finger motif, one DEAD and one DEAH box, a RNA and an ATP binding site, two large RS domains and multiple phosphorylation sites. Expression Embryonic and neonatal brain. Localisation nuclear Function Transcription factor that binds to the AT-rich core sequence of the enhancer element of the AFP gene and downregulates AFP gene expression, possibly involved in neuronal differentiation (ATBF1-A). Homology mouse atbf1, drosophila zfh2 and C. Elegans ZC 123.3 Mutations Somatic Amplification, in one early neural crest derived cell line SJNB-12 under the form of extrachromosomally double minutes, non-syntenic co- amplification with MYC. Absence of ATBF1 expression in alpha-fetoprotein expressing gastric cancer cell lines, lack of ATBF1 expression not due to mutation, deletion or translocation but to strong repression at the transcriptional level. Implicated in Disease Early neural crest derived cell line (SJNB-12). Prognosis unknown Cytogenetics Several structural and numerical chromosomal aberrations and presence of extrachromosomally double minutes and homogenously staining regions, presence of a reciprocal unbalanced Atlas Genet Cytogenet Oncol Haematol 2004; 1 -1- t(8;16)(q24.3;q22.3). Oncogenesis Amplification in one neural crest derived cell line (SJNB-12), non- syntenic co-amplification with MYC. Disease Alpha-fetoprotein producing gastric cancer cell lines (GCIY and Ist-I). Prognosis poor (very malignant and highly metastatic cancer) Oncogenesis Alpha-fetoprotein producing cancer cell lines show absence of ATBF1 expression, lack of ATBF1 expression not due to deletion mutation or translocation but to strong repression at the transcriptional level. External links Nomenclature Hugo ATBF1 GDB ATBF1 Entrez_Gene ATBF1 463 AT-binding transcription factor 1 Cards Atlas ATBF1ID357 GeneCards ATBF1 Ensembl ATBF1 Genatlas ATBF1 GeneLynx ATBF1 eGenome ATBF1 euGene 463 Genomic and cartography ATBF1 - chr16:71378456-71639775 - 16q22.2 (hg17- GoldenPath May_2004) Ensembl ATBF1 - 16q22.2 [CytoView] NCBI Genes Cyto Gene Seq [Map View - NCBI] OMIM Disease map [OMIM] HomoloGene ATBF1 Gene and transcription Genbank
Load more

Recommended publications
  • Genome-Wide Rnai Screening Identifies Human Proteins with A
    RESOURCES Genome-wide RNAi screening identifies human proteins with a regulatory function in the early secretory pathway Jeremy C. Simpson1,7, Brigitte Joggerst2, Vibor Laketa2, Fatima Verissimo2, Cihan Cetin2, Holger Erfle2,6, Mariana G. Bexiga1, Vasanth R. Singan1, Jean-Karim Hériché3, Beate Neumann3, Alvaro Mateos2, Jonathon Blake4, Stephanie Bechtel5, Vladimir Benes4, Stefan Wiemann5, Jan Ellenberg2,3 and Rainer Pepperkok2,7 The secretory pathway in mammalian cells has evolved to facilitate the transfer of cargo molecules to internal and cell surface membranes. Use of automated microscopy-based genome-wide RNA interference screens in cultured human cells allowed us to identify 554 proteins influencing secretion. Cloning, fluorescent-tagging and subcellular localization analysis of 179 of these proteins revealed that more than two-thirds localize to either the cytoplasm or membranes of the secretory and endocytic pathways. The depletion of 143 of them resulted in perturbations in the organization of the COPII and/or COPI vesicular coat complexes of the early secretory pathway, or the morphology of the Golgi complex. Network analyses revealed a so far unappreciated link between early secretory pathway function, small GTP-binding protein regulation, actin cytoskeleton organization and EGF-receptor-mediated signalling. This work provides an important resource for an integrative understanding of global cellular organization and regulation of the secretory pathway in mammalian cells. Within higher eukaryotic cells membrane traffic pathways connect the Extensive efforts over many years have revealed a significant number various membrane-bounded organelles, thereby ensuring that they of regulators associated with the secretory pathway. Early biochemical retain the correct complement of proteins and lipids to maintain approaches to identify individual machinery components have started cellular homeostasis.
    [Show full text]
  • Clinical Validation of the Tempus Xt Next-Generation Targeted Oncology Sequencing Assay
    www.oncotarget.com Oncotarget, 2019, Vol. 10, (No. 24), pp: 2384-2396 Research Paper Clinical validation of the tempus xT next-generation targeted oncology sequencing assay Nike Beaubier1, Robert Tell1, Denise Lau1, Jerod R. Parsons1, Stephen Bush1, Jason Perera1, Shelly Sorrells1, Timothy Baker1, Alan Chang1, Jackson Michuda1, Catherine Iguartua1, Shelley MacNeil1, Kaanan Shah1, Philip Ellis1, Kimberly Yeatts1, Brett Mahon1, Timothy Taxter1, Martin Bontrager1, Aly Khan1, Robert Huether1, Eric Lefkofsky1 and Kevin P. White1 1Tempus Labs Inc., Chicago, IL 60654, USA Correspondence to: Nike Beaubier, email: [email protected] Kevin P. White, email: [email protected] Keywords: tumor profiling, next-generation sequencing assay validation Received: August 03, 2018 Accepted: February 03, 2019 Published: March 22, 2019 Copyright: Beaubier et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT We developed and clinically validated a hybrid capture next generation sequencing assay to detect somatic alterations and microsatellite instability in solid tumors and hematologic malignancies. This targeted oncology assay utilizes tumor- normal matched samples for highly accurate somatic alteration calling and whole transcriptome RNA sequencing for unbiased identification of gene fusion events. The assay was validated with a combination of clinical specimens and cell lines, and recorded a sensitivity of 99.1% for single nucleotide variants, 98.1% for indels, 99.9% for gene rearrangements, 98.4% for copy number variations, and 99.9% for microsatellite instability detection. This assay presents a wide array of data for clinical management and clinical trial enrollment while conserving limited tissue.
    [Show full text]
  • Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene
    Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene Melissa Rotunno, 1 Mary L. McMaster, 1 Joseph Boland, 2 Sara Bass, 2 Xijun Zhang, 2 Laurie Burdett, 2 Belynda Hicks, 2 Sarangan Ravichandran, 3 Brian T. Luke, 3 Meredith Yeager, 2 Laura Fontaine, 4 Paula L. Hyland, 1 Alisa M. Goldstein, 1 NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, Stephen J. Chanock, 5 Neil E. Caporaso, 1 Margaret A. Tucker, 6 and Lynn R. Goldin 1 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 2Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 3Ad - vanced Biomedical Computing Center, Leidos Biomedical Research Inc.; Frederick National Laboratory for Cancer Research, Frederick, MD; 4Westat, Inc., Rockville MD; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; and 6Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA ©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135475 Received: August 19, 2015. Accepted: January 7, 2016. Pre-published: June 13, 2016. Correspondence: [email protected] Supplemental Author Information: NCI DCEG Cancer Sequencing Working Group: Mark H. Greene, Allan Hildesheim, Nan Hu, Maria Theresa Landi, Jennifer Loud, Phuong Mai, Lisa Mirabello, Lindsay Morton, Dilys Parry, Anand Pathak, Douglas R. Stewart, Philip R. Taylor, Geoffrey S. Tobias, Xiaohong R. Yang, Guoqin Yu NCI DCEG Cancer Genomics Research Laboratory: Salma Chowdhury, Michael Cullen, Casey Dagnall, Herbert Higson, Amy A.
    [Show full text]
  • Wo 2010/081001 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 15 July 2010 (15.07.2010) WO 2010/081001 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12Q 1/68 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US20 10/020501 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, ! January 2010 (08.01 .2010) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/143,598 9 January 2009 (09.01 .2009) US (84) Designated States (unless otherwise indicated, for every 61/187,776 17 June 2009 (17.06.2009) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): THE ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, REGENTS OF THE UNIVERSITY OF MICHIGAN TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, [US/US]; 1214 South University, 2nd Floor, Ann Arbor, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, Michigan 48104 (US).
    [Show full text]
  • Understanding the Genetics of Coronary Artery Disease Through Novel Statistical Approaches
    Fakultät für Medizin Deutsches Herzzentrum München - Klinik an der Technischen Universität München Understanding the genetics of coronary artery disease through novel statistical approaches Lingyao Zeng Vollständiger Abdruck der von der Fakultät für Medizin der Technischen Universität München zur Erlangung des akademischen Grades eines Doctor of Philosophy (Ph.D.) genehmigten Dissertation. Vorsitzende/r: Prof. Dr. Dr. Stefan Engelhardt Betreuer/in: Prof. Dr. Adnan Kastrati Prüfer der Dissertation: 1. Prof. Dr. Heribert Schunkert 2. Prof. Dr. Dr. Fabian Theis Die Dissertation wurde am 29.07.2016 bei der Fakultät für Medizin der Technischen Universität München eingereicht und durch die Fakultät für Medizin am 14.09.2016 angenommen. Acknowledgement First of all, I would like to express my sincere gratitude and thanks to my advisor Prof. Heribert Schunkert. It is my honor to join his research group. He has been actively interested in my work and offered tremendous support and guidance at all levels of my PhD research over the last few years. I greatly appreciate all his knowledge, kindness, enthusiasm, and encouragement. I would like to thank the other members of my committee, Prof. Adnan Kastrati and Prof. Fabian Theis. I thank Prof. Adnan Kastrati, who as my supervisor has given me the opportunity to pursue my PhD research at the Deutsches Herzzentrum München and Technische Universität München. I also thank him for the generosity and patience offering the clinical data and descriptions. I thank Prof. Fabian Theis for all his valuable comments and encouragement at both the committee meetings and e:AtheroSysMed project conferences. I am grateful to Prof. Bertram Müller-Myhsok from the Department of Statistical Genetics, Max Planck Institute of Psychiatry, and his team member Dr.
    [Show full text]
  • Role and Regulation of the P53-Homolog P73 in the Transformation of Normal Human Fibroblasts
    Role and regulation of the p53-homolog p73 in the transformation of normal human fibroblasts Dissertation zur Erlangung des naturwissenschaftlichen Doktorgrades der Bayerischen Julius-Maximilians-Universität Würzburg vorgelegt von Lars Hofmann aus Aschaffenburg Würzburg 2007 Eingereicht am Mitglieder der Promotionskommission: Vorsitzender: Prof. Dr. Dr. Martin J. Müller Gutachter: Prof. Dr. Michael P. Schön Gutachter : Prof. Dr. Georg Krohne Tag des Promotionskolloquiums: Doktorurkunde ausgehändigt am Erklärung Hiermit erkläre ich, dass ich die vorliegende Arbeit selbständig angefertigt und keine anderen als die angegebenen Hilfsmittel und Quellen verwendet habe. Diese Arbeit wurde weder in gleicher noch in ähnlicher Form in einem anderen Prüfungsverfahren vorgelegt. Ich habe früher, außer den mit dem Zulassungsgesuch urkundlichen Graden, keine weiteren akademischen Grade erworben und zu erwerben gesucht. Würzburg, Lars Hofmann Content SUMMARY ................................................................................................................ IV ZUSAMMENFASSUNG ............................................................................................. V 1. INTRODUCTION ................................................................................................. 1 1.1. Molecular basics of cancer .......................................................................................... 1 1.2. Early research on tumorigenesis ................................................................................. 3 1.3. Developing
    [Show full text]
  • The Human Gene Connectome As a Map of Short Cuts for Morbid Allele Discovery
    The human gene connectome as a map of short cuts for morbid allele discovery Yuval Itana,1, Shen-Ying Zhanga,b, Guillaume Vogta,b, Avinash Abhyankara, Melina Hermana, Patrick Nitschkec, Dror Friedd, Lluis Quintana-Murcie, Laurent Abela,b, and Jean-Laurent Casanovaa,b,f aSt. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY 10065; bLaboratory of Human Genetics of Infectious Diseases, Necker Branch, Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U980, Necker Medical School, 75015 Paris, France; cPlateforme Bioinformatique, Université Paris Descartes, 75116 Paris, France; dDepartment of Computer Science, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel; eUnit of Human Evolutionary Genetics, Centre National de la Recherche Scientifique, Unité de Recherche Associée 3012, Institut Pasteur, F-75015 Paris, France; and fPediatric Immunology-Hematology Unit, Necker Hospital for Sick Children, 75015 Paris, France Edited* by Bruce Beutler, University of Texas Southwestern Medical Center, Dallas, TX, and approved February 15, 2013 (received for review October 19, 2012) High-throughput genomic data reveal thousands of gene variants to detect a single mutated gene, with the other polymorphic genes per patient, and it is often difficult to determine which of these being of less interest. This goes some way to explaining why, variants underlies disease in a given individual. However, at the despite the abundance of NGS data, the discovery of disease- population level, there may be some degree of phenotypic homo- causing alleles from such data remains somewhat limited. geneity, with alterations of specific physiological pathways under- We developed the human gene connectome (HGC) to over- come this problem.
    [Show full text]
  • Human Social Genomics in the Multi-Ethnic Study of Atherosclerosis
    Getting “Under the Skin”: Human Social Genomics in the Multi-Ethnic Study of Atherosclerosis by Kristen Monét Brown A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Epidemiological Science) in the University of Michigan 2017 Doctoral Committee: Professor Ana V. Diez-Roux, Co-Chair, Drexel University Professor Sharon R. Kardia, Co-Chair Professor Bhramar Mukherjee Assistant Professor Belinda Needham Assistant Professor Jennifer A. Smith © Kristen Monét Brown, 2017 [email protected] ORCID iD: 0000-0002-9955-0568 Dedication I dedicate this dissertation to my grandmother, Gertrude Delores Hampton. Nanny, no one wanted to see me become “Dr. Brown” more than you. I know that you are standing over the bannister of heaven smiling and beaming with pride. I love you more than my words could ever fully express. ii Acknowledgements First, I give honor to God, who is the head of my life. Truly, without Him, none of this would be possible. Countless times throughout this doctoral journey I have relied my favorite scripture, “And we know that all things work together for good, to them that love God, to them who are called according to His purpose (Romans 8:28).” Secondly, I acknowledge my parents, James and Marilyn Brown. From an early age, you two instilled in me the value of education and have been my biggest cheerleaders throughout my entire life. I thank you for your unconditional love, encouragement, sacrifices, and support. I would not be here today without you. I truly thank God that out of the all of the people in the world that He could have chosen to be my parents, that He chose the two of you.
    [Show full text]
  • Variation in Protein Coding Genes Identifies Information Flow
    bioRxiv preprint doi: https://doi.org/10.1101/679456; this version posted June 21, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Animal complexity and information flow 1 1 2 3 4 5 Variation in protein coding genes identifies information flow as a contributor to 6 animal complexity 7 8 Jack Dean, Daniela Lopes Cardoso and Colin Sharpe* 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Institute of Biological and Biomedical Sciences 25 School of Biological Science 26 University of Portsmouth, 27 Portsmouth, UK 28 PO16 7YH 29 30 * Author for correspondence 31 [email protected] 32 33 Orcid numbers: 34 DLC: 0000-0003-2683-1745 35 CS: 0000-0002-5022-0840 36 37 38 39 40 41 42 43 44 45 46 47 48 49 Abstract bioRxiv preprint doi: https://doi.org/10.1101/679456; this version posted June 21, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Animal complexity and information flow 2 1 Across the metazoans there is a trend towards greater organismal complexity. How 2 complexity is generated, however, is uncertain. Since C.elegans and humans have 3 approximately the same number of genes, the explanation will depend on how genes are 4 used, rather than their absolute number.
    [Show full text]
  • Reverse Engineering of Modified Genes by Bayesian Network Analysis Defines Olecm Ular Determinants Critical to the Development of Glioblastoma Brian W
    Florida International University FIU Digital Commons Robert Stempel College of Public Health & Social Environmental Health Sciences Work 5-30-2013 Reverse Engineering of Modified Genes by Bayesian Network Analysis Defines olecM ular Determinants Critical to the Development of Glioblastoma Brian W. Kunkle Department of Environmental Health Sciences, Florida International University Changwon Yoo Department of Biostatistics, Florida International University, [email protected] Deodutta Roy Department of Environmental Health Sciences, Florida International University, [email protected] Follow this and additional works at: https://digitalcommons.fiu.edu/eoh_fac Part of the Medicine and Health Sciences Commons Recommended Citation Kunkle BW, Yoo C, Roy D (2013) Reverse Engineering of Modified Genes by Bayesian Network Analysis Defines Molecular Determinants Critical to the Development of Glioblastoma. PLoS ONE 8(5): e64140. https://doi.org/10.1371/ journal.pone.0064140 This work is brought to you for free and open access by the Robert Stempel College of Public Health & Social Work at FIU Digital Commons. It has been accepted for inclusion in Environmental Health Sciences by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. Reverse Engineering of Modified Genes by Bayesian Network Analysis Defines Molecular Determinants Critical to the Development of Glioblastoma Brian W. Kunkle1, Changwon Yoo2, Deodutta Roy1* 1 Department of Environmental and Occupational Health, Florida International University, Miami, Florida, United States of America, 2 Department of Biostatistics, Florida International University, Miami, Florida, United States of America Abstract In this study we have identified key genes that are critical in development of astrocytic tumors. Meta-analysis of microarray studies which compared normal tissue to astrocytoma revealed a set of 646 differentially expressed genes in the majority of astrocytoma.
    [Show full text]
  • Pattern Discovery and Cancer Gene Identification in Integrated Cancer
    Pattern discovery and cancer gene identification in integrated cancer genomic data Qianxing Moa,b, Sijian Wangc, Venkatraman E. Seshana, Adam B. Olshend, Nikolaus Schultze, Chris Sandere, R. Scott Powersf, Marc Ladanyig, and Ronglai Shena,1 aDepartment of Epidemiology and Biostatistics, eComputational Biology Program, and gDepartment of Pathology and Human Oncology and Pathogenesis Program, Memorial Sloan–Kettering Cancer Center, New York, NY 10065; bDepartment of Medicine and Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030; cDepartment of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI 53792; dDepartment of Epidemiology and Biostatistics, University of California, San Francisco, CA 94107; and fCancer Genome Center, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11797 Edited by Peter J. Bickel, University of California, Berkeley, CA, and approved December 19, 2012 (received for review May 27, 2012) Large-scale integrated cancer genome characterization efforts in- integrates the information to extract biological principles from the cluding the cancer genome atlas and the cancer cell line encyclo- massive amount of data to provide useful insights for advancing pedia have created unprecedented opportunities to study cancer diagnostic, prognostic, and therapeutic strategies. biology in the context of knowing the entire catalog of genetic In a previous publication (8), we proposed an integrative alterations. A clinically important challenge is to discover cancer clustering framework
    [Show full text]
  • Detection of H3k4me3 Identifies Neurohiv Signatures, Genomic
    viruses Article Detection of H3K4me3 Identifies NeuroHIV Signatures, Genomic Effects of Methamphetamine and Addiction Pathways in Postmortem HIV+ Brain Specimens that Are Not Amenable to Transcriptome Analysis Liana Basova 1, Alexander Lindsey 1, Anne Marie McGovern 1, Ronald J. Ellis 2 and Maria Cecilia Garibaldi Marcondes 1,* 1 San Diego Biomedical Research Institute, San Diego, CA 92121, USA; [email protected] (L.B.); [email protected] (A.L.); [email protected] (A.M.M.) 2 Departments of Neurosciences and Psychiatry, University of California San Diego, San Diego, CA 92103, USA; [email protected] * Correspondence: [email protected] Abstract: Human postmortem specimens are extremely valuable resources for investigating trans- lational hypotheses. Tissue repositories collect clinically assessed specimens from people with and without HIV, including age, viral load, treatments, substance use patterns and cognitive functions. One challenge is the limited number of specimens suitable for transcriptional studies, mainly due to poor RNA quality resulting from long postmortem intervals. We hypothesized that epigenomic Citation: Basova, L.; Lindsey, A.; signatures would be more stable than RNA for assessing global changes associated with outcomes McGovern, A.M.; Ellis, R.J.; of interest. We found that H3K27Ac or RNA Polymerase (Pol) were not consistently detected by Marcondes, M.C.G. Detection of H3K4me3 Identifies NeuroHIV Chromatin Immunoprecipitation (ChIP), while the enhancer H3K4me3 histone modification was Signatures, Genomic Effects of abundant and stable up to the 72 h postmortem. We tested our ability to use H3K4me3 in human Methamphetamine and Addiction prefrontal cortex from HIV+ individuals meeting criteria for methamphetamine use disorder or not Pathways in Postmortem HIV+ Brain (Meth +/−) which exhibited poor RNA quality and were not suitable for transcriptional profiling.
    [Show full text]